Rob Volansky

Patients with IgG4-related disease who received obexelimab demonstrated a 56% reduction in flare risk compared with those given placebo at 52 weeks, according to data presented at the EULAR 2026 Congress.

As the presence of ambient AI scribes to record clinical encounters in the exam room grows increasingly common, experts continue to debate over whether this new technology will ultimately be a friend or foe to physicians.“Ambient AI has the potential to bring about significant changes in what has become the elephant in the room for many physicians: the electronic health record,”

The neonatal Fc receptor blocker nipocalimab exhibited significant improvement over placebo in systemic lupus erythematosus at 24 and 52 weeks, according to data presented at the EULAR 2026 Congress.

The novel interleukin-17AA targeted molecule izokibep showed ACR50 response rates of more than 50% in psoriatic arthritis at 52 weeks, according to data presented at EULAR 2026 Congress.

Depression and inflammation may be intimately linked through connections between the brain and the immune system, according a speaker at the EULAR 2026 Congress.

Compounded medications currently represent an estimated 1% to 3% of all prescriptions written in the United States, according to a recent 2025-2026 report issued by the Alliance for Pharmacy Compounding.“There’s a good chance you know someone who has benefited — or whose pet has benefited — from a compounded drug,” read the report, which was released in March.

An analysis of health care workforce data projected significant shortages of rheumatologists in the United States, particularly in the South and

A new CMS proposed rule would reduce the burden of prior authorizations by further shortening payer decision timeframes and increasing transparency, but

Secukinumab was superior to placebo in exhibiting sustained remission at 52 weeks in patients with relapsed polymyalgia rheumatica, according to findings published in the New England Journal of Medicine.“Polymyalgia rheumatica is a common inflammatory disease characterized by pain and stiffness in the shoulders and hips,” John H. Stone, MD, of the division of rheumatology,

In a position statement published earlier this year, the American College of Clinical Pharmacy called for the total withdrawal of direct-to-consumer advertising for medications in the United States. The paper, published in April in the Journal of the American College of Clinical Pharmacy, stated that although such advertisements may increase disease awareness and encourage patient engagement,